{"doi":"10.1038/s41467-024-55200-2","title":"Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial","abstract":"Combined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC. The primary endpoint was the fraction of expanded tumor-associated T-cell receptor (TCR) clones in blood at day 21 as a surrogate measure of anti-tumor immune response. Secondary objectives were safety and feasibility, 2-year disease-free survival (DFS), and predictive value of PD-L1 expression. Forty patients were randomized, 36 received treatment, and 25 were evaluable for the primary endpoint. After cycle 1, there was peripheral expansion of higher proportion of tumor-associated TCR clones in Arm A than in Arm B (p = 0.0025) that remained higher at day 21, meeting the pre-specified endpoint on two-sample T-test (p = 0.052), but not on sensitivity analysis by Wilcoxon test (p = 0.13). At the median follow up of 25.8 months, 2-year DFS was 76% in Arm A and 56% in Arm B (p = 0.28). There were no new safety signals. In conclusion, neoadjuvant ICB prior to CRT was safe and was associated with immunologically and clinically favorable outcomes, warranting larger confirmatory studies.","journal":"Nature Communications","year":2025,"id":510704,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9521,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":227533,"name":"Dmitriy Zamarin","orcid":"0000-0002-0094-0161","position":1,"is_corresponding":false},{"id":256629,"name":"Wei Deng","orcid":"0000-0003-1778-2013","position":2,"is_corresponding":false},{"id":256634,"name":"Heather A. Lankes","orcid":"0000-0001-8814-5033","position":3,"is_corresponding":false},{"id":287367,"name":"Giulio Pesci","orcid":null,"position":4,"is_corresponding":false},{"id":128600,"name":"Hayeon Kim","orcid":"0000-0002-8869-3176","position":5,"is_corresponding":false},{"id":235184,"name":"Junzo Chino","orcid":"0000-0002-3633-9685","position":6,"is_corresponding":false},{"id":218604,"name":"Barbara L. Banbury","orcid":"0000-0001-7332-7117","position":7,"is_corresponding":false},{"id":1368457,"name":"Ned Sherry","orcid":null,"position":8,"is_corresponding":false},{"id":262226,"name":"Elad Sharon","orcid":"0000-0002-0044-9719","position":9,"is_corresponding":false},{"id":307895,"name":"Sharad Ghamande","orcid":"0000-0003-2242-2215","position":10,"is_corresponding":false},{"id":1110101,"name":"C.L. Ferguson","orcid":"0000-0002-5949-6333","position":11,"is_corresponding":false},{"id":258163,"name":"Loren K. Mell","orcid":"0000-0003-2277-6080","position":12,"is_corresponding":false},{"id":655313,"name":"Laura L. Holman","orcid":"0000-0003-1580-5381","position":13,"is_corresponding":false},{"id":438133,"name":"Cara Mathews","orcid":"0000-0001-8461-4568","position":14,"is_corresponding":false},{"id":258149,"name":"David M. O’Malley","orcid":"0000-0002-2828-0177","position":15,"is_corresponding":false},{"id":241550,"name":"Alexander Olawaiye","orcid":"0000-0002-2833-9255","position":16,"is_corresponding":false},{"id":711169,"name":"Elizabeth Hopp","orcid":"0000-0002-0577-0501","position":17,"is_corresponding":false},{"id":280653,"name":"Charles A. Leath","orcid":"0000-0002-4034-6845","position":18,"is_corresponding":false},{"id":918255,"name":"Larry J. Copeland","orcid":"0000-0001-6204-0962","position":19,"is_corresponding":false},{"id":66134,"name":"Robert S. Mannel","orcid":null,"position":20,"is_corresponding":false},{"id":256636,"name":"Roisin E. O’Cearbhaill","orcid":"0000-0001-8217-4554","position":21,"is_corresponding":false},{"id":258142,"name":"Carol Aghajanian","orcid":"0000-0003-0851-3225","position":22,"is_corresponding":false},{"id":243833,"name":"Russell J. Schilder","orcid":null,"position":23,"is_corresponding":false},{"id":235192,"name":"Jyoti Mayadev","orcid":"0000-0003-4786-8192","position":0,"is_corresponding":true}],"reference_count":32,"raw_metadata":null,"created_at":"2026-07-19T02:47:50.575618Z","pmid":"39788967","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}